COST PLUS DRUGS Trademark

Trademark Overview

On Friday, March 11, 2022, a trademark application was filed for COST PLUS DRUGS with the United States Patent and Trademark Office. The USPTO has given the COST PLUS DRUGS trademark a serial number of 97307451. The federal status of this trademark filing is REGISTERED as of Tuesday, November 26, 2024. This trademark is owned by Mark Cuban Cost Plus Drug Company, PBC. The COST PLUS DRUGS trademark is filed in the Treatment & Processing of Materials Services category with the following description:

Custom manufacture of drugs, medications, and pharmaceuticals by pharmaceutical compounders
cost plus drugs

General Information

Serial Number97307451
Word MarkCOST PLUS DRUGS
Filing DateFriday, March 11, 2022
Status700 - REGISTERED
Status DateTuesday, November 26, 2024
Registration Number7582442
Registration DateTuesday, November 26, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesCustom manufacture of drugs, medications, and pharmaceuticals by pharmaceutical compounders
NOT AVAILABLE"DRUGS"

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateWednesday, March 16, 2022
Primary Code040
First Use Anywhere DateTuesday, April 30, 2024
First Use In Commerce DateTuesday, April 30, 2024

Trademark Owner History

Party NameMark Cuban Cost Plus Drug Company, PBC
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLittleton, CO 80123
Party NameMark Cuban Cost Plus Drug Company, PBC
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLittleton, CO 80123

Trademark Events

Event DateEvent Description
Tuesday, March 15, 2022NEW APPLICATION ENTERED
Wednesday, March 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 22, 2022ASSIGNED TO EXAMINER
Wednesday, December 28, 2022NON-FINAL ACTION WRITTEN
Wednesday, December 28, 2022NON-FINAL ACTION E-MAILED
Wednesday, December 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 10, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 5, 2023SUSPENSION LETTER WRITTEN
Wednesday, April 5, 2023LETTER OF SUSPENSION E-MAILED
Wednesday, April 5, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, April 5, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, April 25, 2024FINAL REFUSAL E-MAILED
Tuesday, October 3, 2023REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, April 25, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, April 25, 2024FINAL REFUSAL WRITTEN
Thursday, May 9, 2024TEAS AMENDMENT OF USE RECEIVED
Monday, May 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 13, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, September 20, 2024AMENDMENT TO USE PROCESSING COMPLETE
Thursday, May 9, 2024USE AMENDMENT FILED
Tuesday, October 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 22, 2024USE AMENDMENT ACCEPTED
Friday, September 20, 2024ASSIGNED TO LIE
Tuesday, October 29, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, October 29, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, October 30, 2024APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Tuesday, November 26, 2024REGISTERED-SUPPLEMENTAL REGISTER
Tuesday, November 26, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, October 29, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, October 29, 2024EXAMINER'S AMENDMENT ENTERED

Related Keywords

drugs plus cost pharmaceutical compounders pharmaceuticals medications manufacture custom